ASH Issues New 2026 Guidelines for Diagnosis of Iron Deficiency
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
USA: The American Society of Hematology (ASH) has issued new evidence-based guidelines for diagnosing iron deficiency, recommending higher serum ferritin thresholds across several population groups and specific testing strategies for people with inflammation. The guidance aims to facilitate earlier identification of iron deficiency, including in individuals who have not yet developed anemia.
The guidelines were published in Blood Advances by Jacquelyn M. Powers of Baylor College of Medicine, United States, and colleagues. The multidisciplinary panel noted that iron deficiency is the most common micronutrient deficiency and can progress to anemia when untreated. However, diagnostic thresholds have varied, and existing guidance has been limited by a lack of evidence-based recommendations.
The ASH panel developed the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Evidence reviews examined the prevalence of iron deficiency across populations and studies evaluating diagnostic thresholds through July 2025. The panel also considered clinical impact, high-risk populations, patient preferences, costs, resource requirements, health equity, acceptability, and feasibility.
The five key recommendations are:
- Children aged 9 months to 4 years: ASH suggests using a serum ferritin threshold of ≤20 ng/mL, rather than ≤12 ng/mL, to diagnose iron deficiency in children without known or suspected inflammation. A higher threshold may be needed when inflammation is present. For children older than 4 years through adolescence, ≤20 ng/mL may be applied indirectly, while <30 ng/mL may be appropriate for non-menstruating adolescents.
- Adults who are neither menstruating nor pregnant: A serum ferritin threshold of ≤30 ng/mL is suggested instead of ≤15 ng/mL. For adults with iron deficiency symptoms or ongoing risk factors, a threshold of ≤50 ng/mL may be appropriate to support diagnosis and management decisions.
- Menstruating individuals: ASH suggests a ferritin threshold of ≤30 ng/mL and recommends against relying on ≤15 ng/mL. A threshold of ≤50 ng/mL may be appropriate for those with heavy menstrual bleeding or other abnormal uterine bleeding, iron deficiency symptoms, additional risk factors, upcoming surgery or plans for pregnancy. A detailed menstrual history is also recommended when evaluating abnormal or heavy bleeding.
- Pregnant individuals: A ferritin threshold of ≤30 ng/mL is suggested, while use of ≤15 ng/mL is discouraged. Among pregnant individuals with anemia, ≤50 ng/mL may be appropriate for diagnosing iron deficiency, regardless of whether additional risk factors or symptoms are present.
- Adults with anemia of inflammation: ASH suggests measuring both serum ferritin and transferrin saturation (TSAT) rather than relying on ferritin alone. Iron deficiency may be considered when TSAT is below 20% or ferritin is below 100 ng/mL. TSAT should preferably be measured after a 5- to 9-hour fast, including avoidance of multivitamin or iron supplements during the fasting period. This approach is relevant to conditions including inflammatory bowel disease, infections, cancer, chronic kidney disease, heart failure and rheumatologic disorders.
The guideline panel emphasized that iron deficiency can coexist with other causes of anemia, particularly in inflammatory conditions. Therefore, ferritin and TSAT results should be interpreted alongside the patient's history, examination, underlying disease and relevant disease-specific guidance. No specific recommendation was made for children with inflammation because of insufficient evidence.
The recommendations are intended to prioritize recognition of iron deficiency and timely access to treatment. The panel also identified important evidence gaps, particularly concerning diagnostic thresholds in certain age groups and inflammatory states.
The guidelines have several limitations, including low or very low certainty of evidence for several recommendations and insufficient direct evidence for some populations. Consequently, some thresholds are based on indirect evidence, and further research is needed to establish more precise diagnostic criteria.
Overall, the ASH guidelines provide updated ferritin thresholds and a more context-specific approach to diagnosing iron deficiency. The recommendations emphasize identifying deficiency before or irrespective of the development of anemia, while recognizing that inflammation can alter the interpretation of conventional iron studies.
Reference:
Jacquelyn M Powers, Ming Yeong Lim, Maureen O. Achebe, Imo J Akpan, Michael Auerbach, Megan C Brown, Maria Paula Cardenas, Caroline Cromwell, Thomas G. DeLoughery, Robert E. Fleming, Martina Fraga, George Goshua, Paula D. James, Adam K Lewkowitz, Jori Ellen May, Grace Nnadozie, Frances Ogunnaya, Guillermo J. Ruiz-Arguelles, Michelle Sholzberg, Layla Van Doren, Angela C. Weyand, Michelle Paula Zeller, Muayad Azzam, Ali Choaib, Qais Hamarsha, Hassan Kawtharany, Jana Khawandi, Reem A. Mustafa; American Society of Hematology 2026 guidelines for diagnosis of iron deficiency. Blood Adv 2026; bloodadvances.2025015950. doi: https://doi.org/10.1182/bloodadvances.2025015950
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.